For example, recent pre-clinical modelling demonstrates that triggering receptor expressed on myeloid cells 2 (TREM2) expression in TAMs in several cancers is associated with T-cell exhaustion and anti-PD1 therapy resistance,28,29 and TREM2 antibody therapy is being investigated in cancers with TAMs expressing this molecule,30 although TREM2 relevance in human glioblastoma is yet to be established. The gene discussed is TREM2; the disease is glioblastoma.